KR970705409A - Enteral Vaccine for Vaginal infections - Google Patents

Enteral Vaccine for Vaginal infections

Info

Publication number
KR970705409A
KR970705409A KR1019970701461A KR19970701461A KR970705409A KR 970705409 A KR970705409 A KR 970705409A KR 1019970701461 A KR1019970701461 A KR 1019970701461A KR 19970701461 A KR19970701461 A KR 19970701461A KR 970705409 A KR970705409 A KR 970705409A
Authority
KR
South Korea
Prior art keywords
vaccine
dead
administered
vaginal
adjuvant
Prior art date
Application number
KR1019970701461A
Other languages
Korean (ko)
Inventor
로버트 리웰린 클랜시
Original Assignee
산티노 디기아코모
오스팜 인터내셔날 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산티노 디기아코모, 오스팜 인터내셔날 리미티드 filed Critical 산티노 디기아코모
Publication of KR970705409A publication Critical patent/KR970705409A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Fodder In General (AREA)

Abstract

비-보조제 장용 백신은 질을 감염시키는 죽은 미생물을 함유한다. 미생물은 칸디다 알버칸스와 같은 균류, 가드너엘라 버지날리스 또는 나이서리아 고노리어와 같은 박테리아, 트리코모나스 버지날리스와 같은 원생동물 또는 헤르페스 제니탈리스와 같은 바이러스를 뜻한다. 보조제가 없는 것은 보조제가 있는 조성물에 비하여, 미생물의 제거에 상당한 개량을 나타낸다.Non-adjuvant vaccines contain dead microorganisms that infect vaginal epithelium. The microorganism refers to a fungus such as Candida albanthus, a bacterium such as Gardnerella virginalis or Nyseria gonorrhoea, a protozoan such as Trichomonas virginalis, or a virus such as herpes jenitalis. The absence of adjuvant represents a significant improvement in the removal of microorganisms as compared to compositions with adjuvants.

Description

질 감염용 장 백신(Enteral Vaccine for Vaginal infections)Enteral Vaccine for Vaginal infections

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (14)

질을 감염시키는 죽은 균류, 박테리아 또는 원생동물 유기체로 이루어지는 장용 비-보조제 백신.An enteric non-adjuvant vaccine consisting of dead fungi, bacteria or protozoal organisms that infect vaginal epithelium. 제1항에 있어서, 경구 투여에 사용되는 백신.2. The vaccine according to claim 1, which is used for oral administration. 제1항 또는 제2항에 있어서, 단위 투약량으로 약 109미생물 내지 약 1013미생물을 함유하는 백신.According to claim 1 or 2, wherein about 10 9 to about 10 13 microbial vaccine containing the microorganisms in a unit dose. 제1항, 제2항 또는 제3항에 있어서, 죽은 칸디다 알비칸스를 함유하는 백신.The vaccine of claim 1, 2 or 3, wherein the vaccine contains dead candida albicans. 제1항, 제2항 또는 제3항에 있어서, 죽은 나이서리아 고노리어를 함유하는 백신.The vaccine of claim 1, 2 or 3, wherein the vaccine contains dead Nisseria gonorrhoeae. 제1항, 제2항 또는 제3항에 있어서, 죽은 가드너엘라 버지날리스를 함유하는 백신.4. The vaccine of claim 1, 2 or 3, wherein the vaccine contains dead Gardnerella virginilis. 제1항, 제2항 또는 제3항에 있어서, 죽은 트리코모나스 버지날리스를 함유하는 백신.4. The vaccine of claim 1, 2 or 3, wherein the vaccine contains dead Trichomonas virginylis. 사균을 약학적으로 또는 수의학적으로 수용할 수 있는 담체, 충전제, 희석제 와/또는 기타 보조제와 혼합하여서 하는 제1항 내지 제7항 중 어느 한 항에 따른 백신의 제조 방법.The method for producing a vaccine according to any one of claims 1 to 7, wherein the microorganism is mixed with a pharmaceutically or veterinarily acceptable carrier, filler, diluent and / or other adjuvant. 보조제가 없는 장용 백신의 제조에서 질을 감염시키는 사균의 용도.Use of dead bacteria to infect vaginal epithelium in the manufacture of an adjunctive enteric vaccine. 제1항 내지 제7항 중 어느 한 항에 따른 백신을 장에 투여하여서 하는 사람 또는 동물의 질 감염 예방법.A method for preventing vaginal infections in a human or animal by administering the vaccine according to any one of claims 1 to 7 to the intestines. 제10항에 있어서, 백신을 에스트로겐 수준이 높은 시간에 투여하는 방법.11. The method of claim 10, wherein the vaccine is administered at a high estrogen level. 제11항에 있어서, 에스트로겐-주성분 피임제를 취하지 않은 여성에 있어, 백신을 월경주기 초의 후-월경 기간에 투여하는 방법.12. The method according to claim 11, wherein the vaccine is administered in a post-menstrual period of the menstrual cycle in a woman who has not taken an estrogen-based ingredient contraceptive. 제11항에 있어서, 에스트로겐-주성분 피임제를 취하고 있는 여성에 있어, 백신을 이들의 주기 이외에 언제든지 투여하는 방법.12. The method according to claim 11, wherein the vaccine is administered at any time other than the period of time in a woman taking an estrogen-based ingredient contraceptive. 질의 세균 감염을 예방하기 위하여, 함께 동시에 또는 연속 투여하는, 에스트로겐 활성을 갖는 화합물과 제1항 내지 제7항 중 어느 한 항에 따른 백신으로 이루어지는 제품.A product comprising a compound having an estrogenic activity and a vaccine according to any one of claims 1 to 7 for simultaneous or sequential administration in order to prevent vaginal bacterial infection. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970701461A 1994-09-06 1995-09-05 Enteral Vaccine for Vaginal infections KR970705409A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9417880.3 1994-09-06
GB9417880A GB9417880D0 (en) 1994-09-06 1994-09-06 Vaccine
PCT/IB1995/000766 WO1996007426A1 (en) 1994-09-06 1995-09-05 Enteral vaccine for vaginal infections

Publications (1)

Publication Number Publication Date
KR970705409A true KR970705409A (en) 1997-10-09

Family

ID=10760876

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701461A KR970705409A (en) 1994-09-06 1995-09-05 Enteral Vaccine for Vaginal infections

Country Status (12)

Country Link
EP (1) EP0779817A1 (en)
JP (1) JPH10505083A (en)
KR (1) KR970705409A (en)
CN (1) CN1159760A (en)
AU (1) AU3353095A (en)
CA (1) CA2199255A1 (en)
FI (1) FI970933A (en)
GB (1) GB9417880D0 (en)
IL (1) IL115197A (en)
NO (1) NO971003L (en)
WO (1) WO1996007426A1 (en)
ZA (1) ZA957482B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0834322A3 (en) 1996-10-04 1998-04-22 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Mycosis vaccine
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
EP1303300B1 (en) * 2000-06-19 2010-08-11 Hunter Immunology Limited Compositions and methods for treatment of candidiasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7604311A (en) * 1975-04-25 1976-10-27 Bactex Inc METHOD OF INSULATING PILUS CRYSTALS FROM N-GONORRHOEAE AND METHODS OF USING THE CRYSTALS SO OBTAINED.
ZA767577B (en) * 1976-01-29 1977-11-30 American Cyanamid Co Method of extracting and using antigen and products prepared therefrom
FR2397839A1 (en) * 1977-07-18 1979-02-16 Grimberg Georges Oral vaccine for treating or preventing gastroenteritis - comprises specified killed or attenuated microorganisms
US4220638A (en) * 1978-10-12 1980-09-02 Merck & Co., Inc. Antigenic complex from N. Gonorrhoeae
US4443431A (en) * 1981-05-27 1984-04-17 The United States Of America As Represented By The Department Of Health And Human Services Neisseria gonorrhoeae vaccine
GB8506373D0 (en) * 1985-03-12 1985-04-11 Axon Healthcare Ltd Antigens antibodies
DD268868A1 (en) * 1987-04-03 1989-06-14 Forsch Lungenkrankheiten Und T METHOD FOR BETTER MANUFACTURE OF LOCALLY BIOLOGICAL PRACTICES
US5512288A (en) * 1992-12-04 1996-04-30 University Technologies International, Inc. Giardia vaccine

Also Published As

Publication number Publication date
IL115197A (en) 1999-07-14
CN1159760A (en) 1997-09-17
AU3353095A (en) 1996-03-27
MX9701730A (en) 1997-10-31
NO971003L (en) 1997-05-06
WO1996007426A1 (en) 1996-03-14
ZA957482B (en) 1997-03-06
NO971003D0 (en) 1997-03-05
JPH10505083A (en) 1998-05-19
CA2199255A1 (en) 1996-03-14
FI970933A0 (en) 1997-03-05
GB9417880D0 (en) 1994-10-26
FI970933A (en) 1997-05-05
IL115197A0 (en) 1995-12-31
EP0779817A1 (en) 1997-06-25

Similar Documents

Publication Publication Date Title
JPH0780774B2 (en) Pharmaceutical composition
CA2204277A1 (en) Combined meningitis vaccine
RU97107333A (en) COMPOSITION OF THE MEDICINAL FORM FOR THE TREATMENT OF VENERAL DISEASES AND ITS APPLICATION
KR970705976A (en) USE AND COMPOSITION OF AN ANTI-SEXUALLY TRANSMITTED DISEASES FORMULATION
Asbach Single dose oral administration of cefixime 400mg in the treatment of acute uncomplicated cystitis and gonorrhoea
CA2382887A1 (en) Immunopotentiating compositions
KR950026524A (en) Pharmaceutical composition for the treatment of skin diseases
Chang et al. Effect of roxithromycin on acute toxoplasmosis in mice
KR970705409A (en) Enteral Vaccine for Vaginal infections
Mohr et al. Actinomycosis treated with lincomycin
KR900013971A (en) Purfuromycin and its dosage forms for the treatment of vaginal infections
Muguti et al. Tetanus following human bite
Thadepalli et al. Actinomyces viscosus infections of the chest in humans
AU5643299A (en) Humic acid and its use in the treatment of various conditions
EP1646378B1 (en) Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences
EP0576506B1 (en) Use of benzimidazole anthelmintic in the treatment of microsporidial infections
US4997830A (en) Pharmaceutical composition for the treatment of periodontitis
Burkman et al. A preliminary report of an investigation to study the effectiveness of certain drugs for sterilizing carious dentine
RU2185840C1 (en) Medicinal preparation for prophylaxis and treatment of infectious diseases
Armitage et al. The Use of a New Quinoline Derivative in the Treatment of Infection.
KISTNER et al. Effect of terramycin-polymyxin vaginal tablets on trichomonas and nonspecific vaginitis
KR100190869B1 (en) Veterinary treatment
CN113876930A (en) Compound medicine for preventing and treating porcine reproductive and respiratory syndrome
Worlock THE PREVENTION OF INFECTION IN OPEN FRACTURES: AN EXPERIMENTAL STUDY OF THE EFFECTS OF FRACTURE STABILITY AND OF ANTIBIOTIC THERAPY.
JPS639492B2 (en)

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid